PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29614681-4 2018 Fluvoxamine is a selective serotonin reuptake inhibitor and a potent SIGMAR1 agonist. Fluvoxamine 0-11 sigma non-opioid intracellular receptor 1 Mus musculus 69-76 30728287-8 2019 These findings could have substantial clinical implications, as we further find that fluvoxamine, an antidepressant therapeutic with high affinity for S1R, protects mice from lethal septic shock and dampens the inflammatory response in human blood leukocytes. Fluvoxamine 85-96 sigma non-opioid intracellular receptor 1 Mus musculus 151-154 24396420-0 2014 Effects of BD1047, a sigma1 receptor antagonist, on the expression of mTOR, Camk2gamma and GSK-3beta in fluvoxamine-treated N2a cells. Fluvoxamine 104-115 sigma non-opioid intracellular receptor 1 Mus musculus 21-36 28529139-2 2017 Some SSRIs such as fluvoxamine have agonistic activity towards for the sigma1 receptor, but it is not known whether the effect on the receptor plays a key role in the pharmacological effects. Fluvoxamine 19-30 sigma non-opioid intracellular receptor 1 Mus musculus 71-86 27987210-8 2017 Picrotoxin-induced anhedonia was ameliorated by fluvoxamine and S-(+)-fluoxetine, selective serotonin reuptake inhibitors with high affinity for the sigma1 receptor. Fluvoxamine 48-59 sigma non-opioid intracellular receptor 1 Mus musculus 149-164 27987210-9 2017 The effect of fluvoxamine was blocked by a 5-HT1A or a sigma1 receptor antagonist, and co-administration of the sigma1 receptor agonist (+)-SKF-10047 and the 5-HT1A receptor agonist osemozotan mimicked the effect of fluvoxamine. Fluvoxamine 14-25 sigma non-opioid intracellular receptor 1 Mus musculus 55-70 25316382-3 2015 Here, we demonstrate that chronic stimulation of Sig-1R by treatment with the agonist SA4503 or the SSRI fluvoxamine for 14 days improves depressive-like behaviors in CaMKIV null mice. Fluvoxamine 105-116 sigma non-opioid intracellular receptor 1 Mus musculus 49-55 25704012-3 2015 Preclinical studies showed that some selective serotonin reuptake inhibitors (SSRIs; fluvoxamine, fluoxetine, excitalopram), donepezil, and ifenprodil act as sigma-1 receptor agonists. Fluvoxamine 85-96 sigma non-opioid intracellular receptor 1 Mus musculus 158-174 25704012-5 2015 A study using positron emission tomography have demonstrated that an oral administration of fluvoxamine or donepezil could bind to sigma-1 receptor in the healthy human brain, suggesting that sigma-1 receptor might be involved in the therapeutic mechanisms of these drugs. Fluvoxamine 92-103 sigma non-opioid intracellular receptor 1 Mus musculus 131-147 25704012-5 2015 A study using positron emission tomography have demonstrated that an oral administration of fluvoxamine or donepezil could bind to sigma-1 receptor in the healthy human brain, suggesting that sigma-1 receptor might be involved in the therapeutic mechanisms of these drugs. Fluvoxamine 92-103 sigma non-opioid intracellular receptor 1 Mus musculus 192-208 25704012-6 2015 Moreover, case reports suggest that sigma-1 receptor agonists, including fluvoxamine, and ifenprodil, may be effective in the treatment of cognitive impairment in schizophrenia, delirium in elderly people, and flashbacks in post-traumatic stress disorder. Fluvoxamine 73-84 sigma non-opioid intracellular receptor 1 Mus musculus 36-52 25032855-0 2014 Fluvoxamine alleviates ER stress via induction of Sigma-1 receptor. Fluvoxamine 0-11 sigma non-opioid intracellular receptor 1 Mus musculus 50-66 25032855-3 2014 Fluvoxamine (Flv) is a selective serotonin reuptake inhibitor (SSRI) with a high affinity for Sig-1R. Fluvoxamine 0-11 sigma non-opioid intracellular receptor 1 Mus musculus 94-100 25032855-3 2014 Fluvoxamine (Flv) is a selective serotonin reuptake inhibitor (SSRI) with a high affinity for Sig-1R. Fluvoxamine 13-16 sigma non-opioid intracellular receptor 1 Mus musculus 94-100 25316382-9 2015 Taken together, Sig-1R stimulation by SA4503 or fluvoxamine treatment increased hippocampal neurogenesis, which is closely associated with amelioration of depressive-like behaviors in CaMKIV null mice. Fluvoxamine 48-59 sigma non-opioid intracellular receptor 1 Mus musculus 16-22 25069239-7 2013 Some SSRIs (fluoxetine and fluvoxamine), which have sigma-1 receptor agonistic activity, inhibited the development of methamphetamine-induced behavioral sensitization. Fluvoxamine 27-38 sigma non-opioid intracellular receptor 1 Mus musculus 52-68 23851260-4 2013 Systemic administration of fluvoxamine, a selective 5-HT reuptake inhibitor with agonistic activity towards the sigma1 receptor, increased prefrontal dopamine (DA) levels, and adrenalectomy/castration potentiated this fluvoxamine-induced increase in DA. Fluvoxamine 27-38 sigma non-opioid intracellular receptor 1 Mus musculus 112-127 23851260-4 2013 Systemic administration of fluvoxamine, a selective 5-HT reuptake inhibitor with agonistic activity towards the sigma1 receptor, increased prefrontal dopamine (DA) levels, and adrenalectomy/castration potentiated this fluvoxamine-induced increase in DA. Fluvoxamine 218-229 sigma non-opioid intracellular receptor 1 Mus musculus 112-127 25069239-10 2013 These results suggest that sigma-1 receptor agonistic activity might be involved in the attenuating effects of fluoxetine and fluvoxamine on methamphetamine-induced behavioral sensitization and rewarding effects. Fluvoxamine 126-137 sigma non-opioid intracellular receptor 1 Mus musculus 27-43 21427517-10 2011 The behavioral effects induced by mixed sigma(1)-receptor/SSRI antidepressants, like fluvoxamine or sertraline, may therefore involve a non-selective action at both targets. Fluvoxamine 85-96 sigma non-opioid intracellular receptor 1 Mus musculus 40-57 22293694-7 2012 By contrast, fluvoxamine administration significantly attenuated TAC-induced myocardial hypertrophy concomitant with recovery of Sig-1R expression in LV. Fluvoxamine 13-24 sigma non-opioid intracellular receptor 1 Mus musculus 129-135 22293694-9 2012 The fluvoxamine cardioprotective effect was nullified by treatment with a Sig-1R antagonist, NE-100 (1 mg/kg). Fluvoxamine 4-15 sigma non-opioid intracellular receptor 1 Mus musculus 74-80 22293694-12 2012 Our findings suggest that fluvoxamine protects heart against TAC-induced cardiac dysfunction via upregulation of Sig-1R and stimulation of Sig-1R-mediated Akt-eNOS signaling in mice. Fluvoxamine 26-37 sigma non-opioid intracellular receptor 1 Mus musculus 113-119 22293694-12 2012 Our findings suggest that fluvoxamine protects heart against TAC-induced cardiac dysfunction via upregulation of Sig-1R and stimulation of Sig-1R-mediated Akt-eNOS signaling in mice. Fluvoxamine 26-37 sigma non-opioid intracellular receptor 1 Mus musculus 139-145 22293694-13 2012 This is the first report of a potential role of Sig-1R stimulation by fluvoxamine in preventing cardiac hypertrophy and myocardial injury in TAC mice. Fluvoxamine 70-81 sigma non-opioid intracellular receptor 1 Mus musculus 48-54 21487652-3 2011 RESULTS: Fluvoxamine-induced increases in the extracellular levels of dopamine (DA), but not of 5-HT and noradrenaline, were significantly higher in adrenalectomized/castrated than in sham-operated mice, and this effect was blocked by BD1047, a selective sigma(1) receptor antagonist. Fluvoxamine 9-20 sigma non-opioid intracellular receptor 1 Mus musculus 255-272 21487652-7 2011 CONCLUSIONS: These findings suggest that fluvoxamine enhances prefrontal dopaminergic neurotransmission via both 5-HT reuptake inhibition and sigma(1) receptor activation under the circulating neuroactive steroid-deficient conditions. Fluvoxamine 41-52 sigma non-opioid intracellular receptor 1 Mus musculus 142-159 23044468-8 2013 Moreover, sigma-1 receptor agonists, including the endogenous neurosteroid dehydroepiandosterone (DHEA) and the selective serotonin reuptake inhibitor (SSRI) fluvoxamine, show potent cardioprotective and antidepressive effects in rodents, via sigma-1 receptor stimulation. Fluvoxamine 158-169 sigma non-opioid intracellular receptor 1 Mus musculus 10-26 23044468-8 2013 Moreover, sigma-1 receptor agonists, including the endogenous neurosteroid dehydroepiandosterone (DHEA) and the selective serotonin reuptake inhibitor (SSRI) fluvoxamine, show potent cardioprotective and antidepressive effects in rodents, via sigma-1 receptor stimulation. Fluvoxamine 158-169 sigma non-opioid intracellular receptor 1 Mus musculus 243-259 23041149-0 2012 Involvement of the sigma1 receptor in the antidepressant-like effects of fluvoxamine in the forced swimming test in comparison with the effects elicited by paroxetine. Fluvoxamine 73-84 sigma non-opioid intracellular receptor 1 Mus musculus 19-34 23041149-1 2012 We studied the involvement of the sigma(1) receptor in the antidepressant-like effects of the selective serotonin reuptake inhibitor (SSRI) fluvoxamine in DBA/2 mice using the forced swimming test. Fluvoxamine 140-151 sigma non-opioid intracellular receptor 1 Mus musculus 34-51 23041149-6 2012 These results suggested that the sigma(1) receptor was associated with fluvoxamine-induced antidepressant-like effects but not with paroxetine-induced antidepressant-like effects. Fluvoxamine 71-82 sigma non-opioid intracellular receptor 1 Mus musculus 33-50 21487652-0 2011 Fluvoxamine enhances prefrontal dopaminergic neurotransmission in adrenalectomized/castrated mice via both 5-HT reuptake inhibition and sigma(1) receptor activation. Fluvoxamine 0-11 sigma non-opioid intracellular receptor 1 Mus musculus 136-153 21487652-1 2011 RATIONALE: Fluvoxamine, a selective serotonin (5-HT) reuptake inhibitor (SSRI) and an agonist for the sigma(1) receptors, increases extracellular monoamines in the prefrontal cortex, but it is not known whether the sigma(1) receptor is involved in the neurochemical effect of fluvoxamine. Fluvoxamine 11-22 sigma non-opioid intracellular receptor 1 Mus musculus 102-119 16495935-4 2007 Furthermore, the effect of fluvoxamine on PCP-induced cognitive deficits was antagonized by co-administration of the selective sigma-1 receptor antagonist NE-100 (1 mg/kg/day). Fluvoxamine 27-38 sigma non-opioid intracellular receptor 1 Mus musculus 127-143 20802134-0 2010 Sigma1-receptor stimulation with fluvoxamine ameliorates transverse aortic constriction-induced myocardial hypertrophy and dysfunction in mice. Fluvoxamine 33-44 sigma non-opioid intracellular receptor 1 Mus musculus 0-15 20802134-3 2010 Here, we investigated the role of sigma(1)-receptor (sigma(1)R) stimulation with fluvoxamine on myocardial hypertrophy and cardiac functional recovery. Fluvoxamine 81-92 sigma non-opioid intracellular receptor 1 Mus musculus 53-62 20802134-7 2010 In contrast, fluvoxamine administration significantly attenuated TAC-induced myocardial hypertrophy concomitant with recovery of sigma(1)R expression in the LV. Fluvoxamine 13-24 sigma non-opioid intracellular receptor 1 Mus musculus 129-138 20802134-9 2010 The fluvoxamine cardioprotective effect was nullified by treatment with a sigma(1)R antagonist [NE-100 (1 mg/kg)]. Fluvoxamine 4-15 sigma non-opioid intracellular receptor 1 Mus musculus 74-83 20802134-12 2010 Our findings suggest that fluvoxamine protects against TAC-induced cardiac dysfunction via upregulated sigma(1)R expression and stimulation of sigma(1)R-mediated Akt-eNOS signaling in mice. Fluvoxamine 26-37 sigma non-opioid intracellular receptor 1 Mus musculus 103-112 20802134-12 2010 Our findings suggest that fluvoxamine protects against TAC-induced cardiac dysfunction via upregulated sigma(1)R expression and stimulation of sigma(1)R-mediated Akt-eNOS signaling in mice. Fluvoxamine 26-37 sigma non-opioid intracellular receptor 1 Mus musculus 143-152 20802134-13 2010 This is the first report of a potential role for sigma(1)R stimulation by fluvoxamine in attenuating cardiac hypertrophy and restoring contractility in TAC mice. Fluvoxamine 74-85 sigma non-opioid intracellular receptor 1 Mus musculus 49-58 16495935-9 2007 Therefore, sigma-1 receptor agonists such as fluvoxamine would be potential therapeutic drugs for the treatment of the cognitive deficits of schizophrenia. Fluvoxamine 45-56 sigma non-opioid intracellular receptor 1 Mus musculus 11-27